Prostate Cancer Daily

December 23, 2024

Videos

Peer-to-Peer Clinical Conversations

CLARIFY Trial: Multiday 64Cu-SAR-bisPSMA PET Scans Refine Prostate Cancer Assessment - Luke Nordquist

Luke Nordquist

Zachary Klaassen and Luke Nordquist discuss the CLARIFY trial, which evaluates a novel Copper-64 SAR-bisPSMA PET imaging technique for high-risk prostate cancer patients before surgery.

View

Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen

Silke Gillessen

Silke Gillessen joins Neeraj Agarwal to discuss the results of the STAMPEDE trial's metformin arm.

View

Beyond the Abstracts

Preclinical and Clinical Evidence for Using Perinatal Tissue Allografts in Nerve Sparing Robot Assisted Radical Prostatectomy to Hasten Recovery of Functional Outcomes: A Literature Review - Beyond the Abstract

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy - Beyond the Abstract

Conference Coverage

SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radical Prostatectomy

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.

Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer.

The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI-RADS or TNM

Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.

Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.

Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login